Completing the cycle of investing in research and having that effort and resources improve people’s lives is products on the market. At Emory we are blessed with talented faculty seeking knowledge and innovation in so many interesting areas. This provides my office with rich opportunities to seek partnerships with industry and move research from the lab to the market.

–         Todd Sherer

Waiting twenty years for your discovery to gain FDA approval might test some researchers' resolve. But Mark Goodman, kept his eye on the prize: a new and improved imaging agent. When he first came to Emory he welcomed the chance to continue investigating a molecule that showed promise: carbon-11 choline, a synthetic amino acid that had successfully imaged brain cancer. Read the rest of the story on this webpage.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for 'lorem ipsum' will uncover many web sites still in their infancy. Various versions have evolved over the years, sometimes by accident, sometimes on purpose (injected humour and the like).

Pete Lollar didn't set out to create a treatment for hemophilia. In the 1990s he began researching hemostasis, the process by which a damaged vessel stops losing blood and begins repair. In trying to understand coagulation, the process by which blood changes from a liquid to a gel, he stumbled upon a serendipitous discovery. Read the rest of the story on this webpage.

News & Notes

  • OTT Start-up: AKESOgen Makes Inc. Magazine List of Fasting Growing Companies for Third Time ... View More
  • OTT Start-up: Meissa Vaccines Announces seed Round Investment from FundRx ... View More
  • OTT Start-up: NeurOp $3.5M Receives NIH Award to Support Phase 1 Clinical Trial of NMDA Inhibitor ... View More
  • OTT Start-up: GeoVax Awarded NIH Grant for Zika Vaccine ... View More
  • OTT Start-up: QUE Oncology Lands $16M in Series A Financing ... View More

Featured Innovation

Preventing a Silent Virus

Arash Grakoui, PhD

While we have preventive vaccines for Hepatitis A and B, there is no preventive measure for HCV. Arash and colleagues have discovered HCV mutants that are viable candidates for such a preventive vaccine. A single amino acid (a cysteine) can be mutated to make viral particles non-infective; the immune system may recognize these non-infectious virus particles and build immunity to HCV without being compromised by the active virus.

View More

Hep C Graphic

Recent Twitter Posts